tinlarebant
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stargardt Disease
Conditions
Stargardt Disease
Trial Timeline
Mar 12, 2021 → Aug 15, 2023
NCT ID
NCT05266014About tinlarebant
tinlarebant is a phase 1/2 stage product being developed by Belite Bio for Stargardt Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05266014. Target conditions include Stargardt Disease.
What happened to similar drugs?
0 of 1 similar drugs in Stargardt Disease were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
9
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05266014 | Phase 1/2 | Completed |
Competing Products
9 competing products in Stargardt Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MA09-hRPE | Astellas Pharma | Pre-clinical | 26 |
| MA09-hRPE | Astellas Pharma | Phase 1/2 | 32 |
| avacincaptad pegol + Sham | Astellas Pharma | Phase 2 | 35 |
| MA09-hRPE | Astellas Pharma | Phase 1/2 | 32 |
| hESC-RPE | Astellas Pharma | Pre-clinical | 26 |
| SAR422459 | Sanofi | Phase 1/2 | 24 |
| Long term follow up in all patients who received SAR422459 in previous study TDU13583 | Sanofi | Phase 2 | 39 |
| Tinlarebant + Placebo | Belite Bio | Phase 3 | 37 |
| OCU410ST | Ocugen | Phase 2/3 | 39 |